{
    "clinical_study": {
        "@rank": "152943", 
        "acronym": "AMICI", 
        "arm_group": [
            {
                "arm_group_label": "12.5M MPCs", 
                "arm_group_type": "Experimental", 
                "description": "12.5M Mesenchymal Precursor Cell (MPC) administered via IC infusion"
            }, 
            {
                "arm_group_label": "25M MPCs", 
                "arm_group_type": "Experimental", 
                "description": "25M Mesenchymal Precursor Cell (MPC) administered via IC infusion"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo via IC infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double blind, randomized, placebo controlled study that will enroll 225 subjects\n      with de novo anterior myocardial infarction due to a lesion of the left anterior descending\n      coronary artery undergoing PCI.  Eligible subjects will be enrolled and undergo\n      revascularization of the culprit LAD followed by an intracoronary (IC) delivery of the\n      assigned treatment, infused into the stented culprit artery. The study will determine the\n      safety and feasibility of the IC infusion of investigational MPCs in this patient\n      population."
        }, 
        "brief_title": "Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Clinical symptoms consistent with AMI (pain, etc.) from a minimum of 2 to maximum of\n             12 hours from onset of symptoms to percutaneous coronary intervention (PCI)\n\n          -  De Novo anterior Acute Myocardial Infarct (AMI)\n\n          -  Successful revascularization of the culprit lesion\n\n          -  Female of child bearing potential willing to use contraception and must have negative\n             pregnancy test upon screening\n\n        Key Exclusion Criteria:\n\n          -  Prior AMI, known cardiomyopathy, or hospital admission for heart failure (HF)\n\n          -  Significant valvular disease\n\n          -  Need for staged treatment of coronary artery disease (CAD), or other interventional\n             or surgical procedure to treat heart disease (planned or scheduled)\n\n          -  Cardiogenic shock or hemodynamic instability within 24 hours of randomization\n\n          -  Prior PCI to LAD\n\n          -  Pacemaker, ICD (Implantable Cardioverter Defibrillator), or any other\n             contra-indication for cardiac MRI\n\n          -  Prior or current participation in any stem cell study or any other investigational\n             trial in the past 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "225", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781390", 
            "org_study_id": "ANG.AMI-IC001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "12.5M MPCs", 
                    "25M MPCs"
                ], 
                "intervention_name": "Mesenchymal Precursor Cells (MPC)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute Myocardial Infarction", 
            "STEMI", 
            "Heart Attack", 
            "AMI", 
            "Stem Cells"
        ], 
        "lastchanged_date": "April 29, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kogarah", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2217"
                    }, 
                    "name": "St. George Hospital"
                }, 
                "investigator": {
                    "last_name": "Ananth Prasan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Lambton Heights", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2305"
                    }, 
                    "name": "John Hunter Hospital"
                }, 
                "investigator": {
                    "last_name": "Sukumaran Thambar", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Box Hill", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3128"
                    }, 
                    "name": "Box Hill Hospital"
                }, 
                "investigator": {
                    "last_name": "Gishel New", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Epping", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3076"
                    }, 
                    "name": "The Northern Hospital"
                }, 
                "investigator": {
                    "last_name": "William Van Gaal", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nedlands", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6009"
                    }, 
                    "name": "Sir Charles Gairdner Hospital"
                }, 
                "investigator": {
                    "last_name": "Michelle Ammerer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "zip": "6000"
                    }, 
                    "name": "Royal Perth Hospital"
                }, 
                "investigator": {
                    "last_name": "Shetty Sharad", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussel", 
                        "country": "Belgium", 
                        "zip": "1090"
                    }, 
                    "name": "UZ Brussel Klinische"
                }, 
                "investigator": {
                    "last_name": "Danny Schoors", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kobenhavn", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "Rigshospitalet"
                }, 
                "investigator": {
                    "last_name": "Jens Kastrup", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand", 
                        "zip": "2214"
                    }, 
                    "name": "Christchurch Hospital"
                }, 
                "investigator": {
                    "last_name": "John Elliot", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "New Zealand", 
                        "zip": "3240"
                    }, 
                    "name": "Waikato Hospital"
                }, 
                "investigator": {
                    "last_name": "Gerry Devlin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Denmark", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Prospective, Double Blind, Randomized, Placebo-controlled Clinical Trial of Intracoronary Infusion of Immunoselected, Bone Marrow-derived Stro3 Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction", 
        "overall_contact": {
            "email": "priya.raina@mesoblast.com", 
            "last_name": "Priya Raina", 
            "phone": "212 993 7925"
        }, 
        "overall_contact_backup": {
            "email": "rebecca.cohen@mesoblast.com", 
            "last_name": "Rebecca Cohen", 
            "phone": "212 993 7922"
        }, 
        "overall_official": [
            {
                "affiliation": "Mesoblast, Inc.", 
                "last_name": "Peter Adams, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "UMC Utrecht", 
                "last_name": "Eric Duckers, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Human Research Ethics Committee", 
                "Austria: Agency for Health and Food Safety", 
                "Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "New Zealand: Medsafe", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Occurrence of MACCE events including cardiac death, myocardial infarction, target vessel revascularization, stroke, new or worsening congestive heart failure during index hospitalization and cardiac hospitalizations due to congestive heart failure.", 
            "measure": "Frequency of the total major adverse cardiac and cerebrovascular events (MACCE)", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Angioblast Systems", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Mesoblast, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Mesoblast, Ltd.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Teva Pharmaceuticals USA", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Angioblast Systems", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}